temozolomide has been researched along with Headache in 11 studies
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 9.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
| "Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 5.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
| " The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment." | 3.75 | Efficacy of temozolomide for recurrent embryonal brain tumors in children. ( Chang, KP; Hsu, TR; Wang, CH; Wong, TT, 2009) |
| "Ratio of log-transformed means (intravenous:oral) of area under the concentration-time curve and maximum concentration of drug after dosing for temozolomide and 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) met exposure equivalence criteria (90% confidence interval = 0." | 2.75 | Evaluation of the exposure equivalence of oral versus intravenous temozolomide. ( Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F | 1 |
| Zhang, Y | 1 |
| Wang, N | 1 |
| Song, C | 1 |
| Gao, Y | 1 |
| Diao, X | 1 |
| Zhang, H | 1 |
| Sarper, B | 1 |
| Yaprak Bayrak, B | 1 |
| Halis, H | 1 |
| Alparslan, B | 1 |
| Yeni Bayraktar, H | 1 |
| Bilbao, I | 1 |
| Egaña, N | 1 |
| García, C | 1 |
| Olaizola, I | 1 |
| Yeo, KK | 1 |
| Puscasiu, E | 1 |
| Keating, RF | 1 |
| Rood, BR | 1 |
| Zakaria, Z | 1 |
| Fenton, E | 1 |
| Khalil, A | 1 |
| Sattar, MT | 1 |
| Molnar, P | 1 |
| Wang, CH | 1 |
| Hsu, TR | 1 |
| Wong, TT | 1 |
| Chang, KP | 1 |
| Diez, BD | 1 |
| Statkevich, P | 1 |
| Zhu, Y | 1 |
| Abutarif, MA | 1 |
| Xuan, F | 1 |
| Kantesaria, B | 1 |
| Cutler, D | 1 |
| Cantillon, M | 1 |
| Schwarz, M | 1 |
| Pallotta, MG | 1 |
| Ottaviano, FH | 1 |
| Rojas-Marcos, I | 1 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Delattre, JY | 1 |
| Harkness, KA | 1 |
| Manford, MR | 1 |
| Plummer, ER | 1 |
| Middleton, MR | 1 |
| Jones, C | 1 |
| Olsen, A | 1 |
| Hickson, I | 1 |
| McHugh, P | 1 |
| Margison, GP | 1 |
| McGown, G | 1 |
| Thorncroft, M | 1 |
| Watson, AJ | 1 |
| Boddy, AV | 1 |
| Calvert, AH | 1 |
| Harris, AL | 1 |
| Newell, DR | 1 |
| Curtin, NJ | 1 |
| Steckley, JL | 1 |
| Watling, CJ | 1 |
| Ng, W | 1 |
2 trials available for temozolomide and Headache
| Article | Year |
|---|---|
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
Topics: Administration, Oral; Adult; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Central Ne | 2010 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Dam | 2005 |
9 other studies available for temozolomide and Headache
| Article | Year |
|---|---|
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
Malignant Astroblastoma
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Headache; Huma | 2020 |
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined | 2017 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dac | 2014 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; | 2008 |